Sientra, Inc. (NASDAQ:SIEN) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

A number of other brokerages have also commented on SIEN. Zacks Investment Research lowered shares of Sientra from a “hold” rating to a “sell” rating in a research report on Wednesday, May 17th. Lake Street Capital assumed coverage on shares of Sientra in a research report on Monday, April 17th. They set a “buy” rating and a $11.00 price objective for the company.

Sientra (NASDAQ SIEN) traded up 5.7505% on Thursday, reaching $9.8348. The company’s stock had a trading volume of 289,146 shares. The stock has a 50 day moving average price of $7.83 and a 200-day moving average price of $8.42. The company’s market capitalization is $187.98 million. Sientra has a 1-year low of $6.25 and a 1-year high of $10.37.

Sientra (NASDAQ:SIEN) last released its earnings results on Tuesday, May 9th. The medical instruments supplier reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.49) by $0.12. The firm had revenue of $7.50 million for the quarter, compared to analyst estimates of $5.98 million. Sientra had a negative return on equity of 45.60% and a negative net margin of 148.22%. Sientra’s revenue for the quarter was up 400.0% on a year-over-year basis. Equities analysts predict that Sientra will post ($2.31) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/sientra-inc-sien-rating-increased-to-hold-at-valuengine/1385203.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP bought a new position in shares of Sientra during the first quarter worth approximately $127,000. Geode Capital Management LLC boosted its stake in Sientra by 6.0% in the first quarter. Geode Capital Management LLC now owns 86,792 shares of the medical instruments supplier’s stock worth $730,000 after buying an additional 4,918 shares during the last quarter. Vanguard Group Inc. boosted its stake in Sientra by 85.8% in the first quarter. Vanguard Group Inc. now owns 530,765 shares of the medical instruments supplier’s stock worth $4,469,000 after buying an additional 245,078 shares during the last quarter. Mission Wealth Management LLC acquired a new stake in Sientra during the first quarter worth $104,000. Finally, Segantii Capital Management Ltd boosted its stake in Sientra by 574.1% in the first quarter. Segantii Capital Management Ltd now owns 18,200 shares of the medical instruments supplier’s stock worth $153,000 after buying an additional 15,500 shares during the last quarter. 76.09% of the stock is owned by institutional investors and hedge funds.

About Sientra

Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.